New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies

The purpose: to evaluate the effectiveness of the Delfanto® in the complex therapy of patients with dry eye syndrome of various etiologies and severity of the clinical course.Patients and methods. 114 patients (228 eyes) with dry eye syndrome of various etiologies were examined: 72 patients with chr...

Full description

Saved in:
Bibliographic Details
Main Authors: V. V. Brzheskiy, S. Yu. Golubev, O. I. Lebedev, E. S. Milyudin, A. S. Apostolova, A. V. Surov, E. L. Efimova, E. V. Varlashina, I. N. Gorbachevskaya, V. O. Kirichenko
Format: Article
Language:Russian
Published: Ophthalmology Publishing Group 2020-09-01
Series:Oftalʹmologiâ
Subjects:
Online Access:https://www.ophthalmojournal.com/opht/article/view/1291
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1839571149790380032
author V. V. Brzheskiy
S. Yu. Golubev
O. I. Lebedev
E. S. Milyudin
A. S. Apostolova
A. V. Surov
E. L. Efimova
E. V. Varlashina
I. N. Gorbachevskaya
V. O. Kirichenko
author_facet V. V. Brzheskiy
S. Yu. Golubev
O. I. Lebedev
E. S. Milyudin
A. S. Apostolova
A. V. Surov
E. L. Efimova
E. V. Varlashina
I. N. Gorbachevskaya
V. O. Kirichenko
author_sort V. V. Brzheskiy
collection DOAJ
description The purpose: to evaluate the effectiveness of the Delfanto® in the complex therapy of patients with dry eye syndrome of various etiologies and severity of the clinical course.Patients and methods. 114 patients (228 eyes) with dry eye syndrome of various etiologies were examined: 72 patients with chronic meibomian blepharitis and dysfunction of the meibomian glands (xerosis due to increased evaporation of the tear film), 33 women with perimenopause (a mixed form of xerosis with a predominant decrease in the production of components of the tear film) and 9 persons with Syegren syndrome (xerosis due to a pronounced decrease in tear production). All patients received individually selected tear replacement therapy over the past weeks and the drug was not replaced throughout the study. At the same time, patients with mild and moderate clinical course of SSG for 30 days received Delfanto® at a dosage of 60 mg, and with severe course — 120 mg per day.Results. All patients on the background of complex therapy showed a significant decrease in the severity of subjective manifestations of the dry eye syndrome, an increase in the of the tear film stability and indicators of tear production. At the same time, the dynamics of changes in these parameters of the course of the xerotic process increased as the therapy continued, reaching a maximum by the 30th day. The maximum effect of Delfanto® in the complex therapy of patients with dry eye syndrome was observed in patients with chronic meibomian blepharitis. Moreover, patients with a mild clinical course of cornealconjunctival xerosis were the most susceptible to the therapy.Conclusion. The effectiveness of the complex therapy for patients with dry eye syndrome can be significantly increased by prescribing Delfanto® in a daily dose of 60 mg for mild and moderate xerosis and 120 mg — for severe disease. Delfante® can be recommended for widespread clinical use in complex treatment of patients with various clinical and pathogenetic forms of dry eye syndrome.
format Article
id doaj-art-5213142c20a74f4eae2e8f45597fdf13
institution Matheson Library
issn 1816-5095
2500-0845
language Russian
publishDate 2020-09-01
publisher Ophthalmology Publishing Group
record_format Article
series Oftalʹmologiâ
spelling doaj-art-5213142c20a74f4eae2e8f45597fdf132025-08-04T14:32:22ZrusOphthalmology Publishing GroupOftalʹmologiâ1816-50952500-08452020-09-0117348148910.18008/1816-5095-2020-3-481-489659New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various EtiologiesV. V. Brzheskiy0S. Yu. Golubev1O. I. Lebedev2E. S. Milyudin3A. S. Apostolova4A. V. Surov5E. L. Efimova6E. V. Varlashina7I. N. Gorbachevskaya8V. O. Kirichenko9Saint Petersburg State Pediatric Medical UniversityBranch of the Military Medical Academy named after S.M. KirovOmsk State Medical UniversitySamara State Medical UniversityVision care Clinic Tri3Omsk State Medical UniversitySaint Petersburg State Pediatric Medical UniversityCity clinical hospital No. 3 KrasnodarSaint Petersburg State Pediatric Medical UniversityCity clinical hospital No. 3 KrasnodarThe purpose: to evaluate the effectiveness of the Delfanto® in the complex therapy of patients with dry eye syndrome of various etiologies and severity of the clinical course.Patients and methods. 114 patients (228 eyes) with dry eye syndrome of various etiologies were examined: 72 patients with chronic meibomian blepharitis and dysfunction of the meibomian glands (xerosis due to increased evaporation of the tear film), 33 women with perimenopause (a mixed form of xerosis with a predominant decrease in the production of components of the tear film) and 9 persons with Syegren syndrome (xerosis due to a pronounced decrease in tear production). All patients received individually selected tear replacement therapy over the past weeks and the drug was not replaced throughout the study. At the same time, patients with mild and moderate clinical course of SSG for 30 days received Delfanto® at a dosage of 60 mg, and with severe course — 120 mg per day.Results. All patients on the background of complex therapy showed a significant decrease in the severity of subjective manifestations of the dry eye syndrome, an increase in the of the tear film stability and indicators of tear production. At the same time, the dynamics of changes in these parameters of the course of the xerotic process increased as the therapy continued, reaching a maximum by the 30th day. The maximum effect of Delfanto® in the complex therapy of patients with dry eye syndrome was observed in patients with chronic meibomian blepharitis. Moreover, patients with a mild clinical course of cornealconjunctival xerosis were the most susceptible to the therapy.Conclusion. The effectiveness of the complex therapy for patients with dry eye syndrome can be significantly increased by prescribing Delfanto® in a daily dose of 60 mg for mild and moderate xerosis and 120 mg — for severe disease. Delfante® can be recommended for widespread clinical use in complex treatment of patients with various clinical and pathogenetic forms of dry eye syndrome.https://www.ophthalmojournal.com/opht/article/view/1291dry eye syndrometreatmentantioxidantsdelfanto®
spellingShingle V. V. Brzheskiy
S. Yu. Golubev
O. I. Lebedev
E. S. Milyudin
A. S. Apostolova
A. V. Surov
E. L. Efimova
E. V. Varlashina
I. N. Gorbachevskaya
V. O. Kirichenko
New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
Oftalʹmologiâ
dry eye syndrome
treatment
antioxidants
delfanto®
title New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
title_full New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
title_fullStr New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
title_full_unstemmed New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
title_short New Opportunities for Complex Therapy in Patients with Dry Eye Syndrome of Various Etiologies
title_sort new opportunities for complex therapy in patients with dry eye syndrome of various etiologies
topic dry eye syndrome
treatment
antioxidants
delfanto®
url https://www.ophthalmojournal.com/opht/article/view/1291
work_keys_str_mv AT vvbrzheskiy newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT syugolubev newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT oilebedev newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT esmilyudin newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT asapostolova newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT avsurov newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT elefimova newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT evvarlashina newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT ingorbachevskaya newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies
AT vokirichenko newopportunitiesforcomplextherapyinpatientswithdryeyesyndromeofvariousetiologies